Human CXCL8 knockout PC-3 cell lysate
Be the first to review this product! Submit a review
|
(0 Publication)
CXCL8 KO cell lysate available now. KO validated by Next Generation Sequencing, Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, Homozygous: 22% 11 bp deletion, 24% 7 bp deletion, 54% 2 bp deletion in exon 2.
View Alternative Names
(Ala-IL-8)77, (Ser-IL-8)72, 9.00E+03, Beta thromboglobulin like protein, C-X-C motif chemokine 8, CEF-4, CXCL8, Emoctakin, GCP-1, GCP/IL-8 protein I, GCP/IL-8 protein II, GCP/IL-8 protein III, GCP/IL-8 protein IV, GCP/IL-8 protein V, GCP/IL-8 protein VI, Granulocyte chemotactic protein 1, IL-8(1-77), IL-8(9-77), IL8/NAP1 form I, IL8/NAP1 form II, IL8/NAP1 form III, IL8/NAP1 form IV, IL8/NAP1 form V, IL8/NAP1 form VI, IL8_HUMAN, Inteleukin 8, LECT, LUCT, LYNAP, Lymphocyte-derived neutrophil-activating factor, MDNCF, MDNCF-b, MDNCF-c, MONAP, Monocyte-derived neutrophil chemotactic factor, Monocyte-derived neutrophil-activating peptide, NAP-1, Neutrophil activating peptide 1, Neutrophil-activating factor, Neutrophil-activating protein 1, Protein 3-10C, SCYB 8, Small inducible cytokine subfamily B member 8, T-cell chemotactic factor, TSG 1, chemokine, CXC motif, ligand 8
- WB
Lab
Western blot - Human CXCL8 knockout PC-3 cell lysate (AB275520)
Lane 1 : Wild-type PC-3 Brefeldin A (ab120299)-treated (5 μg/ml, 5 h) cell lysate 30 μg
Lane 2 : Wild-type PC-3 LPS-treated (2 μg/ml, 6 h) with Brefeldin A (ab120299) (5 μg/ml, 5 h) cell lysate 30 μg
Lane 3 : CXCL8 knockout PC-3 Brefeldin A (ab120299)-treated (5 μg/ml, 5 h) cell lysate 30 μg
Lane 4 : CXCL8 knockout PC-3 LPS-treated (2 μg/ml, 6 h) with Brefeldin A (ab120299) (5 μg/ml, 5 h) cell lysate 30 μg
Lane 5 : A431 cell lysate 30 μg
Lane 6 : HCT116 cell lysate 30 μg
Lanes 1 - 6 : Merged signal (red and green). Green - ab235584 observed at 10 kDa. Red - loading control ab8245 (Mouse anti-GAPDH antibody [6C5]) observed at 37kDa.
ab235584 was shown to react with IL-8 in wild-type PC-3 cells in Western blot with loss of signal observed in CXCL8 knockout cell line ab273743 (knockout cell lysate ab275520). Wild-type PC-3 and CXCL8 knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in fluorescent western blot (TBS-based) blocking solution before incubation with ab235584 and ab8245 (Mouse anti-GAPDH antibody [6C5]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-IL-8 antibody [EPR22994-255] (<a href='/en-us/products/primary-antibodies/il-8-antibody-epr22994-255-ab235584'>ab235584</a>) at 1/1000 dilution
Lane 1:
Wild-type PC-3 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 μg/ml, 5 h) cell lysate at 30 µg
Lane 2:
Wild-type PC-3 LPS-treated (2 μg/ml, 6 h) with Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) (5 μg/ml, 5 h) cell lysate at 30 µg
Lane 2:
Western blot - Human CXCL8 knockout PC-3 cell line (<a href='/en-us/products/cell-lines/human-cxcl8-knockout-pc-3-cell-line-ab273743'>ab273743</a>)
Lane 3:
CXCL8 knockout PC-3 Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>)-treated (5 μg/ml, 5 h) cell lysate at 30 µg
Lane 4:
CXCL8 knockout PC-3 LPS-treated (2 μg/ml, 6 h) with Brefeldin A (<a href='/en-us/products/biochemicals/brefeldin-a-inhibitor-of-adp-ribosylation-factor-ab120299'>ab120299</a>) (5 μg/ml, 5 h) cell lysate at 30 µg
Lane 5:
A431 cell lysate at 30 µg
Lane 6:
HCT116 cell lysate at 30 µg
Predicted band size: 11 kDa
Observed band size: 10 kDa
false
- NGS
Supplier Data
Next Generation Sequencing - Human CXCL8 knockout PC-3 cell lysate (AB275520)
Allele-2 : 7bp deletion in exon 2.
- NGS
Supplier Data
Next Generation Sequencing - Human CXCL8 knockout PC-3 cell lysate (AB275520)
Allele-3 : 2bp deletion in exon 2.
- NGS
Supplier Data
Next Generation Sequencing - Human CXCL8 knockout PC-3 cell lysate (AB275520)
Allele-1 : 11bp deletion in exon 2.
Reactivity data
Product details
Knockout cell lysate achieved by CRISPR/Cas9.
Treatments:
Human CXCL8 knockout PC3 cell lysate - Brefeldin A (5 μg/ml, 5h)
Human wild-type PC3 cell lysate - Brefeldin A (5 μg/ml, 5h)
Human CXCL8 knockout PC3 cell lysate - LPS (2 μg/ml, 6h) and Brefeldin A (5 μg/ml, 5h)
Human wild-type PC3 cell lysate - LPS (2 μg/ml, 6h) and Brefeldin A (5 μg/ml, 5h)
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our limited use license and patent pages.
What's included?
Properties and storage information
Gene name
Gene editing type
Gene editing method
Knockout validation
Shipped at conditions
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
IL-8 functions as a chemoattractant for neutrophils and lymphocytes facilitating their movement towards the site of infection or injury. It does not form part of a larger protein complex but operates individually to enhance immune cell migration. IL-8 possesses unique binding motifs allowing it to interact with specific receptors namely CXCR1 and CXCR2 on target cells. This binding triggers cellular responses leading to effective immune surveillance and response to inflammatory stimuli.
Pathways
IL-8 operates within important inflammatory and immune response pathways. It forms a part of the NF-κB signaling cascade which activates in response to stress signals promoting the expression of other inflammatory mediators. Additionally it engages in the mitogen-activated protein kinase (MAPK) pathway influencing cellular responses such as proliferation and differentiation. The interaction of IL-8 with these pathways highlights its role in modulating immune responses and highlights its interaction with other proteins such as TNF-α and IL-1β.
Cell culture
Biosafety level
EU: 1 US: 1
Adherent/suspension
Adherent
Gender
Male
Complementary Products
Primary Antibodies
AB242515
Anti-IL-8 antibody [EPR19358-37] - BSA and Azide free (Capture)
BOND RX™ Validated|RabMAb|Recombinant|KO Validated
![Flow Cytometry (Intracellular) - Anti-IL-8 antibody [EPR19358-37] - BSA and Azide free (Capture) (AB242515)](https://content.abcam.com/products/images/il-8-antibody-epr19358-37-bsa-and-azide-free-capture-ab242515--flow-cytometry-intracellular-img441722.jpg)
- 0
- 0
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com